Clinical Practice Guideline

Acromegaly

November 01, 2014

Guideline

Table

Appendix

 

Full Guideline: Acromegaly: An Endocrine Society Clinical Practice Guideline
JCEM November 2014
Laurence Katznelson, Edward R. Laws, Jr., Shlomo Melmed, Mark E. Molitch, Mohammad Hassan Murad, Andrea Utz, John A. H. Wass

Objective:

The aim was to formulate clinical practice guidelines for acromegaly.

Background:

Acromegaly is a chronic disorder caused by GH hypersecretion. GH circulates and stimulates production of IGF-1 from the liver and systemic tissues; IGF-1 in large part mediates the somatic and metabolic effects of GH. Hypersecretion of GH leads to excess production of IGF-1, leading to a multisystem disease characterized by somatic overgrowth, multiple comorbidities, premature mortality, and physical disfigurement. A multidisciplinary approach is critical for the management of acromegaly.

Using an evidence-based approach, this acromegaly guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including:

  • the appropriate biochemical assessment
  • a therapeutic algorithm, including use of medical monotherapy or combination therapy
  • and management during pregnancy

arrow Read the Full Guideline

Clinical Practice Guideline Mobile App
Access guideline recommendations, patient information, and clinical education modules for a range of endocrine topics plus dozens of interactive decision algorithms and other point-of-care tools.

Clinical Practice Guideline Mobile App

Download our CPG Mobile App

Access guideline recommendations, patient information, and clinical education modules for a range of endocrine topics plus dozens of interactive decision algorithms and other point-of-care tools.

Newly Designed CPG Mobile App
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.